Revolution Medicines (RVMD) Cash from Investing Activities (2019 - 2026)

Revolution Medicines has reported Cash from Investing Activities for 8 years, with the latest figure at $172.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 1182.29% year-over-year to $172.6 million; the trailing twelve-month figure through Mar 2026 stood at $306.6 million (up 195.11% YoY), and the FY2025 full-year result was $118.1 million, up 121.29% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $172.6 million, up from $74.9 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $172.6 million in Q1 2026, with the low at -$392.9 million in Q4 2024.
• Average Cash from Investing Activities over 5 years is -$37.1 million, with a median of $4.0 million recorded in 2023.
• Year-over-year, Cash from Investing Activities surged 1806.67% in 2022 and plunged 6305.36% in 2024.
• Tracing RVMD's Cash from Investing Activities over 5 years: stood at -$7.1 million in 2022, then plunged by 5254.76% to -$380.4 million in 2023, then declined by 3.29% to -$392.9 million in 2024, then soared by 119.06% to $74.9 million in 2025, then surged by 130.52% to $172.6 million in 2026.
• The last three Cash from Investing Activities figures came in at $172.6 million (Q1 2026), $74.9 million (Q4 2025), and $24.8 million (Q3 2025), per Business Quant data.

Peer Comparison